{"id":348119,"date":"2025-08-25T13:58:41","date_gmt":"2025-08-25T13:58:41","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-galectin-therapeutics\/"},"modified":"2025-08-25T13:58:41","modified_gmt":"2025-08-25T13:58:41","slug":"how-to-buy-galectin-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/","title":{"rendered":"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Galectin Therapeutics Inc. (GALT) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131, g\u00fcncel fiyat analizini, 2025-2030 tahminlerini ve bu umut vadeden biyotek hisse senedi i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejilerini \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Galectin Therapeutics Inc. (GALT) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131, g\u00fcncel fiyat analizini, 2025-2030 tahminlerini ve bu umut vadeden biyotek hisse senedi i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejilerini \u00f6\u011frenin."},"intro":"Karaci\u011fer hastal\u0131\u011f\u0131 tedavisinde devrim yaratabilecek bir biyotek \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Galectin Therapeutics Inc. (GALT), deneyimli yat\u0131r\u0131mc\u0131lar\u0131 ve yeni ba\u015flayanlar\u0131 heyecanland\u0131ran klasik y\u00fcksek riskli, y\u00fcksek getirili f\u0131rsat\u0131 temsil ediyor. \u00d6nc\u00fc ila\u00e7lar\u0131 belapectin, MASH sirozu i\u00e7in umut verici sonu\u00e7lar g\u00f6sterirken, bu 4 dolarl\u0131k hisse \u00e7oklu kat getiri sa\u011flayabilir ya da biyotek volatilitesi hakk\u0131nda de\u011ferli dersler verebilir. 2025 y\u0131l\u0131nda GALT'\u0131 bu kadar \u00e7ekici k\u0131lan unsurlar\u0131 ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Karaci\u011fer hastal\u0131\u011f\u0131 tedavisinde devrim yaratabilecek bir biyotek \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Galectin Therapeutics Inc. (GALT), deneyimli yat\u0131r\u0131mc\u0131lar\u0131 ve yeni ba\u015flayanlar\u0131 heyecanland\u0131ran klasik y\u00fcksek riskli, y\u00fcksek getirili f\u0131rsat\u0131 temsil ediyor. \u00d6nc\u00fc ila\u00e7lar\u0131 belapectin, MASH sirozu i\u00e7in umut verici sonu\u00e7lar g\u00f6sterirken, bu 4 dolarl\u0131k hisse \u00e7oklu kat getiri sa\u011flayabilir ya da biyotek volatilitesi hakk\u0131nda de\u011ferli dersler verebilir. 2025 y\u0131l\u0131nda GALT'\u0131 bu kadar \u00e7ekici k\u0131lan unsurlar\u0131 ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Performans\u0131 ve Kritik Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Galectin Therapeutics Inc. (GALT) NASDAQ'ta <strong>4,10 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin belapectin i\u00e7in FDA onay\u0131 ba\u015fvurusunda bulunmas\u0131 bekleniyor.<\/p> <p><strong>FDA Kararlar\u0131n\u0131n GALT Hissesini Nas\u0131l Etkiledi\u011fi<\/strong><\/p> <p>Son d\u00f6neme bak\u0131ld\u0131\u011f\u0131nda, klinik deneme sonu\u00e7lar\u0131 b\u00fcy\u00fck fiyat dalgalanmalar\u0131na yol a\u00e7t\u0131:<\/p> <ul> <li><strong>Haziran 2025<\/strong>: NAVIGATE denemesinin \u00f6n verileri bir gecede <strong>%20 hisse art\u0131\u015f\u0131<\/strong> yaratt\u0131<\/li> <li><strong>14 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131, y\u0131ll\u0131k bazda 12,4 milyon dolardan 7,6 milyon dolara d\u00fc\u015fen zararlar ve %66 azalan 3,3 milyon dolarl\u0131k Ar-Ge giderleri g\u00f6sterdi<\/li> <li><strong>Temmuz 2025<\/strong>: Y\u00f6netim kurulu ba\u015fkan\u0131ndan al\u0131nan 10 milyon dolarl\u0131k kredi hatt\u0131, operasyonel s\u00fcreyi Haziran 2026'ya kadar uzatt\u0131<\/li> <\/ul> <p>Desen a\u00e7\u0131k: olumlu klinik veriler GALT'\u0131 y\u00fckseltirken, herhangi bir aksilik dramatik d\u00fc\u015f\u00fc\u015flere neden oluyor. Yakla\u015fan FDA ba\u015fvurusu \u015fimdiye kadarki en b\u00fcy\u00fck kataliz\u00f6r.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: 1,19 $'dan 4,10 $'a<\/h2> <p>Galectin Therapeutics son alt\u0131 ayda ola\u011fan\u00fcst\u00fc bir <strong>%240 kazan\u00e7<\/strong> sa\u011flad\u0131 ve m\u00fccadele eden bir biyotek \u015firketinden umut vadeden klinik a\u015fama \u015firketine d\u00f6n\u00fc\u015ft\u00fc:<\/p> <table> <thead> <tr><th>Ay<\/th><th>Fiyat Aral\u0131\u011f\u0131<\/th><th>% De\u011fi\u015fim<\/th><th>Ana Sebep<\/th><\/tr> <\/thead> <tbody> <tr><td>Mart 2025<\/td><td>1,19 $-1,82 $<\/td><td>-%22,29<\/td><td>Piyasa \u015f\u00fcphesi<\/td><\/tr> <tr><td>Nisan 2025<\/td><td>1,12 $-1,48 $<\/td><td>+%12,30<\/td><td>Erken deneme iyimserli\u011fi<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>1,21 $-1,63 $<\/td><td>-%4,38<\/td><td>K\u00e2r realizasyonu<\/td><\/tr> <tr><td>Haziran 2025<\/td><td>1,27 $-3,90 $<\/td><td>+%61,07<\/td><td>NAVIGATE deneme verisi a\u00e7\u0131klamas\u0131<\/td><\/tr> <tr><td>Temmuz 2025<\/td><td>2,07 $-3,73 $<\/td><td>+%73,73<\/td><td>Kredi hatt\u0131 sa\u011fland\u0131<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>3,75 $-4,10 $<\/td><td>+%5,67<\/td><td>2. \u00e7eyrek kazan\u00e7lar\u0131 beklentiyi a\u015ft\u0131<\/td><\/tr> <\/tbody> <\/table> <p>Bu patlay\u0131c\u0131 b\u00fcy\u00fcme rastgele de\u011fildi\u2014somut klinik ilerleme ve iyile\u015fen finansal y\u00f6netimle e\u015f zamanl\u0131 ger\u00e7ekle\u015fti. \u015eirket, net zararlar\u0131 y\u0131ll\u0131k bazda %39 azaltt\u0131 ve \u00f6nc\u00fc programlar\u0131na odaklanmay\u0131 s\u00fcrd\u00fcrd\u00fc.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak:<\/p> <ul> <li><strong>2025 (Y\u0131l Sonu)<\/strong>: 6,00 $ hedefi mevcut seviyelerden <strong>%46 y\u00fckseli\u015f<\/strong> anlam\u0131na geliyor. Bu, ba\u015far\u0131l\u0131 FDA ba\u015fvurusu ve devam eden olumlu deneme verileri varsay\u0131m\u0131yla \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/li> <li><strong>2026<\/strong>: FDA onay\u0131 gecikirse veya ek denemeler gerekirse beklenen i\u015flem aral\u0131\u011f\u0131 1,25 $-2,72 $<\/li> <li><strong>2028<\/strong>: Patent konular\u0131 ve rekabetin ortaya \u00e7\u0131kmas\u0131yla 1,40 $-2,00 $ aral\u0131\u011f\u0131na d\u00fc\u015f\u00fc\u015f \u00f6ng\u00f6r\u00fcl\u00fcyor<\/li> <li><strong>2030<\/strong>: Olduk\u00e7a spek\u00fclatif\u2014ticari kabul durumuna ba\u011fl\u0131 olarak 0,50 $ (ba\u015far\u0131s\u0131zl\u0131k) ile 20 $+ (b\u00fcy\u00fck ba\u015far\u0131) aras\u0131nda de\u011fi\u015febilir<\/li> <\/ul> <p>K\u0131sa vadeli iyimserlik ile uzun vadeli belirsizlik aras\u0131ndaki ayr\u0131\u015fma, biyotek yat\u0131r\u0131m\u0131n\u0131n ikili do\u011fas\u0131n\u0131 vurguluyor. \u015eu anda analistler, t\u00fcm takip eden firmalardan <strong>\"G\u00fc\u00e7l\u00fc Al\"<\/strong> konsens\u00fcs derecesiyle b\u00fcy\u00fck \u00f6l\u00e7\u00fcde iyimser.<\/p> <h2>\u26a0\ufe0f Risk Analizi: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <p><strong>Y\u00fcksek Volatilite Riskleri<\/strong><\/p> <ul> <li>G\u00fcnl\u00fck %13'\u00fc a\u015fan dalgalanmalar yayg\u0131n<\/li> <li>Klinik deneme aksilikleri ayl\u0131k kazan\u00e7lar\u0131 an\u0131nda silebilir<\/li> <li>A\u011fustos 2025'te temerr\u00fct olas\u0131l\u0131\u011f\u0131 %3,81'e y\u00fckseldi<\/li> <\/ul> <p><strong>Reg\u00fclasyon Riskleri<\/strong><\/p> <ul> <li>FDA reddi, tek varl\u0131k \u015firketi i\u00e7in felaket olur<\/li> <li>Ek deneme gereksinimleri 23,8 milyon dolarl\u0131k nakit rezervini t\u00fcketebilir<\/li> <li>Onay gecikmesi, rakiplerin MASH pazar\u0131na girmesine olanak tan\u0131yabilir<\/li> <\/ul> <p><strong>Finansal Riskler<\/strong><\/p> <ul> <li>Azalan zararlar\u0131na ra\u011fmen hala nakit yak\u0131yor (son \u00e7eyrekte 7,6 milyon $)<\/li> <li>Geni\u015fleme i\u00e7in gelecekte finansman veya ortakl\u0131klara ba\u011f\u0131ml\u0131<\/li> <li>Belapectin d\u0131\u015f\u0131 gelir \u00e7e\u015fitlili\u011fi s\u0131n\u0131rl\u0131<\/li> <\/ul> <h2>\ud83d\udfe2 2025 \u0130\u00e7in Olumlu Sinyaller<\/h2> <p><strong>Klinik \u0130lerleme<\/strong><\/p> <ul> <li>NAVIGATE denemesi karaci\u011fer sertli\u011fini azaltmada s\u00fcrd\u00fcr\u00fclebilir etkinlik g\u00f6steriyor<\/li> <li>Tedavi kolundaki hastalarda hastal\u0131k ilerlemesi daha az<\/li> <li>18 ay\u0131 a\u015fan tedavi s\u00fcresince tutarl\u0131 sonu\u00e7lar<\/li> <\/ul> <p><strong>Finansal \u0130yile\u015fme<\/strong><\/p> <ul> <li>Verimli deneme y\u00f6netimiyle Ar-Ge giderlerinde %66 azalma<\/li> <li>10 milyon dolarl\u0131k kredi hatt\u0131 Haziran 2026'ya kadar operasyonlar\u0131 destekliyor<\/li> <li>Net zarar azalmas\u0131 maliyet disiplini g\u00f6steriyor<\/li> <\/ul> <p><strong>Pazar Potansiyeli<\/strong><\/p> <ul> <li>MASH sirozu \u00e7ok milyar dolarl\u0131k pazar f\u0131rsat\u0131 sunuyor<\/li> <li>Belirli hasta pop\u00fclasyonunda ilk hareket avantaj\u0131<\/li> <li>Analistlerin %100 \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesiyle g\u00fc\u00e7l\u00fc g\u00f6r\u00fc\u015f\u00fc<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 GALT gibi y\u00fcksek riskli biyotek hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferlik b\u00fcy\u00fck al\u0131m yerine, kritik tarihlerde (FDA ba\u015fvurusu \u00f6ncesi, kazan\u00e7 sonras\u0131) par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: Volatilite nedeniyle sermayenizi %15-20 stop-loss emirleriyle koruyun<\/li> <li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: Kas\u0131m FDA ba\u015fvurusu haberleri ve ortakl\u0131k duyurular\u0131n\u0131 izleyin<\/li> <\/ol> <p>Esprili bir yorum: \"GALT ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014deneyler ba\u015far\u0131l\u0131 oldu\u011funda inan\u0131lmaz heyecan verici, ama ba\u015far\u0131s\u0131z olunca patlay\u0131c\u0131 reaksiyonlara haz\u0131rl\u0131kl\u0131 olun!\"<\/p> <h2>\u2705 Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir i\u015flem platformu se\u00e7in<\/td><td>NASDAQ listeleri ve biyotek hisseleri sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Volatilite nedeniyle k\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"GALT\" sembol\u00fcn\u00fc aray\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Dalgal\u0131 hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Komisyon oranlar\u0131n\u0131 kontrol edin\u2014k\u00fc\u00e7\u00fck i\u015flemlerde %1'in alt\u0131nda hedefleyin<\/td><\/tr> <tr><td>6<\/td><td>Fiyat uyar\u0131lar\u0131 kurun<\/td><td>FDA haberleri ve kazan\u00e7 duyurular\u0131n\u0131 takip edin<\/td><\/tr> <tr><td>7<\/td><td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td><td>K\u00e2r realizasyonu ve stop-loss seviyelerini \u00f6nceden belirleyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option'un Yeni Biyotek Yat\u0131r\u0131mc\u0131lar\u0131na \u00c7ekicili\u011fi<\/h2> <p>Galectin Therapeutics gibi \u015firketlerle ilgilenenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece <strong>5 $<\/strong> ile yat\u0131r\u0131m teorilerini \u00f6nemli risk olmadan test edebilirsiniz\u2014biyotek volatilite kal\u0131plar\u0131n\u0131 \u00f6\u011frenmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge ile 1 dakikal\u0131k KYC s\u00fcreci, klinik deneme haberlerine h\u0131zl\u0131 tepki vermenizi sa\u011flar<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100'den fazla y\u00f6ntem\u2014biyotek kazan\u00e7lar\u0131n\u0131 h\u0131zl\u0131ca g\u00fcvence alt\u0131na almak i\u00e7in kritik<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, biyoteknoloji gibi volatil sekt\u00f6rlere daha b\u00fcy\u00fck miktarlar yat\u0131rmadan \u00f6nce g\u00fcven olu\u015fturmak i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Galectin Therapeutics: Konumland\u0131rma ve Potansiyel<\/h2> <p>Galectin Therapeutics, rekabetin yo\u011fun ancak potansiyel olarak k\u00e2rl\u0131 MASH (Metabolik disfonksiyonla ili\u015fkili steatohepatit) tedavi pazar\u0131nda faaliyet g\u00f6steriyor. \u015eirketin galectin-3 inhibit\u00f6r\u00fcne odaklanmas\u0131, karaci\u011fer fibrozisi ve siroz tedavisinde yenilik\u00e7i bir yakla\u015f\u0131m\u0131 temsil ediyor.<\/p> <p>\u015eu anda yakla\u015f\u0131k 262 milyon dolar de\u011ferinde olan Galectin, piyasa de\u011ferinin mevcut gelirden \u00e7ok potansiyeli yans\u0131tt\u0131\u011f\u0131 klasik bir \"pipeline hikayesi\"dir. \u015eirketin t\u00fcm de\u011feri belapectin'in ba\u015far\u0131s\u0131na ba\u011fl\u0131 olup, hem b\u00fcy\u00fck f\u0131rsatlar hem de \u00f6nemli riskler bar\u0131nd\u0131r\u0131yor.<\/p> <p><strong>2025'ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Galectin'in y\u00f6netim kurulu ba\u015fkan\u0131 Richard E. Uihlein, Temmuz 2025'te ki\u015fisel olarak 10 milyon dolarl\u0131k kredi hatt\u0131 sa\u011flad\u0131\u2014\u015firketin beklentileri ve zorluklar\u0131 hakk\u0131nda derin bilgiye sahip birinden g\u00fc\u00e7l\u00fc bir g\u00fcven oyu.<\/p> <table> <thead> <tr><th>\u00d6l\u00e7\u00fct<\/th><th>De\u011fer<\/th><th>\u00d6nemi<\/th><\/tr> <\/thead> <tbody> <tr><td>G\u00fcncel Fiyat<\/td><td>4,10 $<\/td><td>Mart diplerinden %240 art\u0131\u015f<\/td><\/tr> <tr><td>Piyasa De\u011feri<\/td><td>262M $<\/td><td>Klinik a\u015fama biyotek i\u00e7in tipik<\/td><\/tr> <tr><td>Nakit Yeterlili\u011fi<\/td><td>Haziran 2026'ya kadar<\/td><td>K\u0131sa vadeli operasyonlar i\u00e7in yeterli<\/td><\/tr> <tr><td>Analist Hedefi<\/td><td>6,00 $<\/td><td>%46 yukar\u0131 potansiyel<\/td><\/tr> <tr><td>G\u00fcnl\u00fck Hacim<\/td><td>253.780 hisse<\/td><td>Perakende yat\u0131r\u0131mc\u0131lar i\u00e7in yeterli likidite<\/td><\/tr> <\/tbody> <\/table>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Performans\u0131 ve Kritik Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Galectin Therapeutics Inc. (GALT) NASDAQ&#8217;ta <strong>4,10 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin belapectin i\u00e7in FDA onay\u0131 ba\u015fvurusunda bulunmas\u0131 bekleniyor.<\/p>\n<p><strong>FDA Kararlar\u0131n\u0131n GALT Hissesini Nas\u0131l Etkiledi\u011fi<\/strong><\/p>\n<p>Son d\u00f6neme bak\u0131ld\u0131\u011f\u0131nda, klinik deneme sonu\u00e7lar\u0131 b\u00fcy\u00fck fiyat dalgalanmalar\u0131na yol a\u00e7t\u0131:<\/p>\n<ul>\n<li><strong>Haziran 2025<\/strong>: NAVIGATE denemesinin \u00f6n verileri bir gecede <strong>%20 hisse art\u0131\u015f\u0131<\/strong> yaratt\u0131<\/li>\n<li><strong>14 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131, y\u0131ll\u0131k bazda 12,4 milyon dolardan 7,6 milyon dolara d\u00fc\u015fen zararlar ve %66 azalan 3,3 milyon dolarl\u0131k Ar-Ge giderleri g\u00f6sterdi<\/li>\n<li><strong>Temmuz 2025<\/strong>: Y\u00f6netim kurulu ba\u015fkan\u0131ndan al\u0131nan 10 milyon dolarl\u0131k kredi hatt\u0131, operasyonel s\u00fcreyi Haziran 2026&#8217;ya kadar uzatt\u0131<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131k: olumlu klinik veriler GALT&#8217;\u0131 y\u00fckseltirken, herhangi bir aksilik dramatik d\u00fc\u015f\u00fc\u015flere neden oluyor. Yakla\u015fan FDA ba\u015fvurusu \u015fimdiye kadarki en b\u00fcy\u00fck kataliz\u00f6r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: 1,19 $&#8217;dan 4,10 $&#8217;a<\/h2>\n<p>Galectin Therapeutics son alt\u0131 ayda ola\u011fan\u00fcst\u00fc bir <strong>%240 kazan\u00e7<\/strong> sa\u011flad\u0131 ve m\u00fccadele eden bir biyotek \u015firketinden umut vadeden klinik a\u015fama \u015firketine d\u00f6n\u00fc\u015ft\u00fc:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>% De\u011fi\u015fim<\/th>\n<th>Ana Sebep<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mart 2025<\/td>\n<td>1,19 $-1,82 $<\/td>\n<td>-%22,29<\/td>\n<td>Piyasa \u015f\u00fcphesi<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>1,12 $-1,48 $<\/td>\n<td>+%12,30<\/td>\n<td>Erken deneme iyimserli\u011fi<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>1,21 $-1,63 $<\/td>\n<td>-%4,38<\/td>\n<td>K\u00e2r realizasyonu<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>1,27 $-3,90 $<\/td>\n<td>+%61,07<\/td>\n<td>NAVIGATE deneme verisi a\u00e7\u0131klamas\u0131<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>2,07 $-3,73 $<\/td>\n<td>+%73,73<\/td>\n<td>Kredi hatt\u0131 sa\u011fland\u0131<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>3,75 $-4,10 $<\/td>\n<td>+%5,67<\/td>\n<td>2. \u00e7eyrek kazan\u00e7lar\u0131 beklentiyi a\u015ft\u0131<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Bu patlay\u0131c\u0131 b\u00fcy\u00fcme rastgele de\u011fildi\u2014somut klinik ilerleme ve iyile\u015fen finansal y\u00f6netimle e\u015f zamanl\u0131 ger\u00e7ekle\u015fti. \u015eirket, net zararlar\u0131 y\u0131ll\u0131k bazda %39 azaltt\u0131 ve \u00f6nc\u00fc programlar\u0131na odaklanmay\u0131 s\u00fcrd\u00fcrd\u00fc.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak:<\/p>\n<ul>\n<li><strong>2025 (Y\u0131l Sonu)<\/strong>: 6,00 $ hedefi mevcut seviyelerden <strong>%46 y\u00fckseli\u015f<\/strong> anlam\u0131na geliyor. Bu, ba\u015far\u0131l\u0131 FDA ba\u015fvurusu ve devam eden olumlu deneme verileri varsay\u0131m\u0131yla \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/li>\n<li><strong>2026<\/strong>: FDA onay\u0131 gecikirse veya ek denemeler gerekirse beklenen i\u015flem aral\u0131\u011f\u0131 1,25 $-2,72 $<\/li>\n<li><strong>2028<\/strong>: Patent konular\u0131 ve rekabetin ortaya \u00e7\u0131kmas\u0131yla 1,40 $-2,00 $ aral\u0131\u011f\u0131na d\u00fc\u015f\u00fc\u015f \u00f6ng\u00f6r\u00fcl\u00fcyor<\/li>\n<li><strong>2030<\/strong>: Olduk\u00e7a spek\u00fclatif\u2014ticari kabul durumuna ba\u011fl\u0131 olarak 0,50 $ (ba\u015far\u0131s\u0131zl\u0131k) ile 20 $+ (b\u00fcy\u00fck ba\u015far\u0131) aras\u0131nda de\u011fi\u015febilir<\/li>\n<\/ul>\n<p>K\u0131sa vadeli iyimserlik ile uzun vadeli belirsizlik aras\u0131ndaki ayr\u0131\u015fma, biyotek yat\u0131r\u0131m\u0131n\u0131n ikili do\u011fas\u0131n\u0131 vurguluyor. \u015eu anda analistler, t\u00fcm takip eden firmalardan <strong>&#8220;G\u00fc\u00e7l\u00fc Al&#8221;<\/strong> konsens\u00fcs derecesiyle b\u00fcy\u00fck \u00f6l\u00e7\u00fcde iyimser.<\/p>\n<h2>\u26a0\ufe0f Risk Analizi: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<p><strong>Y\u00fcksek Volatilite Riskleri<\/strong><\/p>\n<ul>\n<li>G\u00fcnl\u00fck %13&#8217;\u00fc a\u015fan dalgalanmalar yayg\u0131n<\/li>\n<li>Klinik deneme aksilikleri ayl\u0131k kazan\u00e7lar\u0131 an\u0131nda silebilir<\/li>\n<li>A\u011fustos 2025&#8217;te temerr\u00fct olas\u0131l\u0131\u011f\u0131 %3,81&#8217;e y\u00fckseldi<\/li>\n<\/ul>\n<p><strong>Reg\u00fclasyon Riskleri<\/strong><\/p>\n<ul>\n<li>FDA reddi, tek varl\u0131k \u015firketi i\u00e7in felaket olur<\/li>\n<li>Ek deneme gereksinimleri 23,8 milyon dolarl\u0131k nakit rezervini t\u00fcketebilir<\/li>\n<li>Onay gecikmesi, rakiplerin MASH pazar\u0131na girmesine olanak tan\u0131yabilir<\/li>\n<\/ul>\n<p><strong>Finansal Riskler<\/strong><\/p>\n<ul>\n<li>Azalan zararlar\u0131na ra\u011fmen hala nakit yak\u0131yor (son \u00e7eyrekte 7,6 milyon $)<\/li>\n<li>Geni\u015fleme i\u00e7in gelecekte finansman veya ortakl\u0131klara ba\u011f\u0131ml\u0131<\/li>\n<li>Belapectin d\u0131\u015f\u0131 gelir \u00e7e\u015fitlili\u011fi s\u0131n\u0131rl\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 2025 \u0130\u00e7in Olumlu Sinyaller<\/h2>\n<p><strong>Klinik \u0130lerleme<\/strong><\/p>\n<ul>\n<li>NAVIGATE denemesi karaci\u011fer sertli\u011fini azaltmada s\u00fcrd\u00fcr\u00fclebilir etkinlik g\u00f6steriyor<\/li>\n<li>Tedavi kolundaki hastalarda hastal\u0131k ilerlemesi daha az<\/li>\n<li>18 ay\u0131 a\u015fan tedavi s\u00fcresince tutarl\u0131 sonu\u00e7lar<\/li>\n<\/ul>\n<p><strong>Finansal \u0130yile\u015fme<\/strong><\/p>\n<ul>\n<li>Verimli deneme y\u00f6netimiyle Ar-Ge giderlerinde %66 azalma<\/li>\n<li>10 milyon dolarl\u0131k kredi hatt\u0131 Haziran 2026&#8217;ya kadar operasyonlar\u0131 destekliyor<\/li>\n<li>Net zarar azalmas\u0131 maliyet disiplini g\u00f6steriyor<\/li>\n<\/ul>\n<p><strong>Pazar Potansiyeli<\/strong><\/p>\n<ul>\n<li>MASH sirozu \u00e7ok milyar dolarl\u0131k pazar f\u0131rsat\u0131 sunuyor<\/li>\n<li>Belirli hasta pop\u00fclasyonunda ilk hareket avantaj\u0131<\/li>\n<li>Analistlerin %100 &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesiyle g\u00fc\u00e7l\u00fc g\u00f6r\u00fc\u015f\u00fc<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 GALT gibi y\u00fcksek riskli biyotek hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferlik b\u00fcy\u00fck al\u0131m yerine, kritik tarihlerde (FDA ba\u015fvurusu \u00f6ncesi, kazan\u00e7 sonras\u0131) par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: Volatilite nedeniyle sermayenizi %15-20 stop-loss emirleriyle koruyun<\/li>\n<li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: Kas\u0131m FDA ba\u015fvurusu haberleri ve ortakl\u0131k duyurular\u0131n\u0131 izleyin<\/li>\n<\/ol>\n<p>Esprili bir yorum: &#8220;GALT ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014deneyler ba\u015far\u0131l\u0131 oldu\u011funda inan\u0131lmaz heyecan verici, ama ba\u015far\u0131s\u0131z olunca patlay\u0131c\u0131 reaksiyonlara haz\u0131rl\u0131kl\u0131 olun!&#8221;<\/p>\n<h2>\u2705 Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyotek hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Volatilite nedeniyle k\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;GALT&#8221; sembol\u00fcn\u00fc aray\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Dalgal\u0131 hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Komisyon oranlar\u0131n\u0131 kontrol edin\u2014k\u00fc\u00e7\u00fck i\u015flemlerde %1&#8217;in alt\u0131nda hedefleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>FDA haberleri ve kazan\u00e7 duyurular\u0131n\u0131 takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td>\n<td>K\u00e2r realizasyonu ve stop-loss seviyelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option&#8217;un Yeni Biyotek Yat\u0131r\u0131mc\u0131lar\u0131na \u00c7ekicili\u011fi<\/h2>\n<p>Galectin Therapeutics gibi \u015firketlerle ilgilenenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece <strong>5 $<\/strong> ile yat\u0131r\u0131m teorilerini \u00f6nemli risk olmadan test edebilirsiniz\u2014biyotek volatilite kal\u0131plar\u0131n\u0131 \u00f6\u011frenmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge ile 1 dakikal\u0131k KYC s\u00fcreci, klinik deneme haberlerine h\u0131zl\u0131 tepki vermenizi sa\u011flar<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100&#8217;den fazla y\u00f6ntem\u2014biyotek kazan\u00e7lar\u0131n\u0131 h\u0131zl\u0131ca g\u00fcvence alt\u0131na almak i\u00e7in kritik<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, biyoteknoloji gibi volatil sekt\u00f6rlere daha b\u00fcy\u00fck miktarlar yat\u0131rmadan \u00f6nce g\u00fcven olu\u015fturmak i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Galectin Therapeutics: Konumland\u0131rma ve Potansiyel<\/h2>\n<p>Galectin Therapeutics, rekabetin yo\u011fun ancak potansiyel olarak k\u00e2rl\u0131 MASH (Metabolik disfonksiyonla ili\u015fkili steatohepatit) tedavi pazar\u0131nda faaliyet g\u00f6steriyor. \u015eirketin galectin-3 inhibit\u00f6r\u00fcne odaklanmas\u0131, karaci\u011fer fibrozisi ve siroz tedavisinde yenilik\u00e7i bir yakla\u015f\u0131m\u0131 temsil ediyor.<\/p>\n<p>\u015eu anda yakla\u015f\u0131k 262 milyon dolar de\u011ferinde olan Galectin, piyasa de\u011ferinin mevcut gelirden \u00e7ok potansiyeli yans\u0131tt\u0131\u011f\u0131 klasik bir &#8220;pipeline hikayesi&#8221;dir. \u015eirketin t\u00fcm de\u011feri belapectin&#8217;in ba\u015far\u0131s\u0131na ba\u011fl\u0131 olup, hem b\u00fcy\u00fck f\u0131rsatlar hem de \u00f6nemli riskler bar\u0131nd\u0131r\u0131yor.<\/p>\n<p><strong>2025&#8217;ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Galectin&#8217;in y\u00f6netim kurulu ba\u015fkan\u0131 Richard E. Uihlein, Temmuz 2025&#8217;te ki\u015fisel olarak 10 milyon dolarl\u0131k kredi hatt\u0131 sa\u011flad\u0131\u2014\u015firketin beklentileri ve zorluklar\u0131 hakk\u0131nda derin bilgiye sahip birinden g\u00fc\u00e7l\u00fc bir g\u00fcven oyu.<\/p>\n<table>\n<thead>\n<tr>\n<th>\u00d6l\u00e7\u00fct<\/th>\n<th>De\u011fer<\/th>\n<th>\u00d6nemi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>G\u00fcncel Fiyat<\/td>\n<td>4,10 $<\/td>\n<td>Mart diplerinden %240 art\u0131\u015f<\/td>\n<\/tr>\n<tr>\n<td>Piyasa De\u011feri<\/td>\n<td>262M $<\/td>\n<td>Klinik a\u015fama biyotek i\u00e7in tipik<\/td>\n<\/tr>\n<tr>\n<td>Nakit Yeterlili\u011fi<\/td>\n<td>Haziran 2026&#8217;ya kadar<\/td>\n<td>K\u0131sa vadeli operasyonlar i\u00e7in yeterli<\/td>\n<\/tr>\n<tr>\n<td>Analist Hedefi<\/td>\n<td>6,00 $<\/td>\n<td>%46 yukar\u0131 potansiyel<\/td>\n<\/tr>\n<tr>\n<td>G\u00fcnl\u00fck Hacim<\/td>\n<td>253.780 hisse<\/td>\n<td>Perakende yat\u0131r\u0131mc\u0131lar i\u00e7in yeterli likidite<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n"},"faq":[{"question":"Galectin Therapeutics Inc. (GALT) hisseleri nereden al\u0131nabilir?","answer":"GALT hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"GALT hissesinin riskleri nelerdir?","answer":"Y\u00fcksek volatilite, klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 b\u00fcy\u00fck fiyat dalgalanmalar\u0131, FDA onay s\u00fcrecindeki belirsizlikler ve finansal riskler GALT hissesinin ba\u015fl\u0131ca risklerindendir."},{"question":"FDA onay\u0131 GALT hissesini nas\u0131l etkiler?","answer":"Ba\u015far\u0131l\u0131 FDA onay\u0131 hisse fiyat\u0131nda \u00f6nemli art\u0131\u015flara yol a\u00e7abilirken, reddedilmesi veya gecikmesi b\u00fcy\u00fck d\u00fc\u015f\u00fc\u015flere neden olabilir."},{"question":"GALT hissesine yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss emirleri kullan\u0131n ve FDA ba\u015fvurusu gibi \u00f6nemli kataliz\u00f6rleri takip edin."},{"question":"Pocket Option biyotek yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama s\u00fcreci ve \u00e7ok \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile Pocket Option, biyotek volatilitesini \u00f6\u011frenmek ve k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamak i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Galectin Therapeutics Inc. (GALT) hisseleri nereden al\u0131nabilir?","answer":"GALT hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"GALT hissesinin riskleri nelerdir?","answer":"Y\u00fcksek volatilite, klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 b\u00fcy\u00fck fiyat dalgalanmalar\u0131, FDA onay s\u00fcrecindeki belirsizlikler ve finansal riskler GALT hissesinin ba\u015fl\u0131ca risklerindendir."},{"question":"FDA onay\u0131 GALT hissesini nas\u0131l etkiler?","answer":"Ba\u015far\u0131l\u0131 FDA onay\u0131 hisse fiyat\u0131nda \u00f6nemli art\u0131\u015flara yol a\u00e7abilirken, reddedilmesi veya gecikmesi b\u00fcy\u00fck d\u00fc\u015f\u00fc\u015flere neden olabilir."},{"question":"GALT hissesine yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss emirleri kullan\u0131n ve FDA ba\u015fvurusu gibi \u00f6nemli kataliz\u00f6rleri takip edin."},{"question":"Pocket Option biyotek yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama s\u00fcreci ve \u00e7ok \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile Pocket Option, biyotek volatilitesini \u00f6\u011frenmek ve k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamak i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T13:58:41+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T13:58:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/\",\"name\":\"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-25T13:58:41+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T13:58:41+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T13:58:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/","name":"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-25T13:58:41+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galectin-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Galectin Therapeutics Inc. (GALT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galectin Therapeutics Inc. (GALT) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":348122,"slug":"how-to-buy-galectin-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Galectin Therapeutics Inc. (GALT) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Galectin Therapeutics Inc. (GALT)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-galectin-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":348120,"slug":"how-to-buy-galectin-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Galectin Therapeutics Inc. (GALT) - Investimento em a\u00e7\u00f5es da Galectin Therapeutics Inc. (GALT)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-galectin-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=348119"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348119\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=348119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=348119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=348119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}